Pharma & Healthcare – the latest on FDA proposed antibacterial soap rule, China’s boost its oversight of drug production and more.
Antibacterial soap makers would need to prove efficacy under proposed FDA rules by Brady Dennis Published on Washington Post
Manufacturers of antibacterial hand soaps and body washes would have to prove that their products are safe to use over time and perform better than ordinary soap and water to keep them on the market, according to regulations proposed Monday by the Food and Drug Administration… [ Read More ]
China rounds up counterfeiters as the FDA boosts its oversight there by Eric Palmer Published on Fierce Pharma
China agreed this month to allow the U.S. FDA to send more people there so it can boost its oversight of Chinese drug production. But as if to prove that it has the situation under control, Chinese authorities this weekend reported rounding up 1,300 suspected counterfeiters and confiscating $362 million worth of fake drugs and raw materials… [ Read More ]
Recent Trends in Class Action and Aggregate Litigation in the Life Sciences Industry by Thomas Sullivan,R. Brendan Fee, Thomas Ayala Published on jdsupra
For the last several years, the life sciences industry has been fertile ground for class action and aggregate litigation. Developments in this area have driven several trends, including state consumer fraud claims, securities class actions, antitrust class actions, and aggregate litigation brought by private healthcare insurers and state attorneys general… [ Read More ]
Live Industry News
Follow @ACI_Pharma and @ACI_Health
Join ACI Pharmaceuticals/Biotech/Life Sciences Experts Group
Join ACI Healthcare: Legal, Regulatory, and Compliance Experts Group
Related Events
For a complete list of all Pharma upcoming events: Click Here
For a complete list of all Healthcare upcoming events: Click Here
To download past Pharma conference materials: Click Here
To download past Healthcare conference materials: Click Here